Axe Compute Inc.'s SEC filings document the company's transition to an enterprise GPU compute infrastructure and digital asset treasury business. Material-event reports cover operating and financial results, the former Predictive Oncology name history, capital-structure changes, and enterprise infrastructure agreements involving dedicated GPU capacity and AI-focused high-speed storage.
The filings also record governance and executive-compensation matters, including board and officer appointments, resignations, employment agreements, and separation arrangements. Additional disclosure categories include shareholder voting matters, risk references tied to ATH token volatility, liquidity sources, and the company's public-company reporting obligations as Nasdaq-listed AGPU.
Axe Compute Inc. (symbol: AGPU) is the issuer of record for a Form 8-K filing submitted to the SEC.
Axe Compute Inc. (AGPU) director Theodore Zhu reported buying common stock in two open-market transactions on September 8, 2026. He purchased 5,000 shares at $10.875 per share and an additional 3,750 shares at $11.72 per share, for a total of 8,750 shares acquired directly. No Rule 10b5-1 trading plan is reported.
Axe Compute Inc. (symbol: AGPU) is the issuer of record for a Form 4 filing submitted to the SEC. Zhu Theodore reported acquisition or exercise transactions in this Form 4 filing.
Axe Compute Inc. (AGPU) reported that director Theodore Zhu received a grant of 2,420 shares of Common Stock on July 1, 2026 as compensation for service on the board of directors. Following this award, Zhu directly holds 7,564 shares of Axe Compute Inc. common stock. No Rule 10b5-1 trading plan is reported in connection with this grant.
Axe Compute Inc. (symbol: AGPU) is the issuer of record for a Form 4 filing submitted to the SEC. ST. CLAIR GREGORY SR reported acquisition or exercise transactions in this Form 4 filing.
Axe Compute Inc. (AGPU) reported that director Gregory St. Clair Sr. received an equity award of 2,420 shares of Common Stock on July 1, 2026. The shares were issued as compensation for his service on the company’s board of directors, bringing his direct holdings to 17,566 shares.
Axe Compute Inc. (symbol: AGPU) is the issuer of record for a Form 4 filing submitted to the SEC. Nuzum Charles Lee Sr reported acquisition or exercise transactions in this Form 4 filing.
Axe Compute Inc. (AGPU) director Nuzum Charles Lee Sr reported receiving a grant of 2,420 shares of Common Stock on July 1, 2026. The shares were issued as compensation for his service on the company’s board of directors, bringing his directly held stake to 22,808 shares.
Axe Compute Inc. (symbol: AGPU) is the issuer of record for a Form 4 filing submitted to the SEC. Hawryluk Matthew reported acquisition or exercise transactions in this Form 4 filing.
Axe Compute Inc. (AGPU) reported that director Matthew Hawryluk received a grant of 1,716 shares of Common Stock on July 1, 2026 as compensation for his service on the company’s board of directors. After this award, he directly holds 13,443 shares of Axe Compute common stock.
Axe Compute Inc. (AGPU) reported that director Daniel E. Handley received a grant of 1,716 shares of Common Stock on July 1, 2026, classified as a grant, award, or other acquisition and issued as compensation for service on the board of directors. Following this grant, Handley directly holds 12,756 shares of Axe Compute Inc. common stock. No Rule 10b5-1 trading plan is reported for this transaction.
Axe Compute Inc. announced that it has entered into agreements with Duos Technologies Group, Inc. for 55 MW of new AI data center capacity across multiple U.S. locations. The agreements represent over $500 million in expected aggregate payments for dedicated capacity.
The expansion builds on the companies’ existing 10 MW deployment in Georgia, which Duos is in the process of delivering for Axe Compute. Initial project readiness for the new capacity is targeted to begin in late 2026 and continue into early 2027, subject to construction, commissioning, performance testing, and other conditions.
Axe Compute and Duos have also executed nonbinding term sheets for minority equity investments by Axe Compute in project entities, with Axe Compute expected to hold 49% of the equity interests. These investments remain subject to definitive documentation, closing conditions, and approval processes of both companies, and the disclosure includes extensive forward-looking statement cautions.
Axe Compute Inc. reported rapid top-line growth but much larger losses as it pivots into AI compute services supported by crypto assets. Revenue for the six months ended June 30, 2026 rose to $3.3 million from $0.1 million, driven by GPU compute contracts rather than the legacy drug discovery business.
The company posted a six‑month net loss of $24.9 million versus $4.5 million a year earlier, mainly due to $17.4 million of losses on ATH digital assets held in its Strategic Compute Reserve and higher operating expenses. Cash and cash equivalents were $21.9 million, with digital assets at $11.3 million, and management believes liquidity is sufficient for at least 12 months.
Contract liabilities climbed to $60.8 million, reflecting prepaid GPU services, with remaining performance obligations scheduled through 2029. In April 2026 Axe signed a $260 million, 36‑month NVIDIA B300 infrastructure contract and in July 2026 secured three additional contracts totaling over $2.8 billion, while also taking on $262.6 million in multi‑year compute purchase commitments.
Axe Compute Inc. reported second-quarter 2026 revenue of $3.2 million, up sharply from $35 thousand in Q1 2026 and $3 thousand a year earlier, reflecting the first full quarter of compute-services revenue under the Axe Compute Access model. The company signed more than $2.8 billion of new Axe Compute Build contracts in July, bringing 2026 total contract value to more than $3 billion and an expected annualized run rate of more than $696 million upon full deployment.
The quarter showed a net loss of $17.2 million, or $0.87 per share, driven largely by a $13.1 million non-cash loss on digital assets. Adjusted EBITDA was approximately ($4.9 million), including about ($0.9 million) from the legacy Drug Discovery Services segment. Contract liabilities, largely customer prepayments that are generally non-cancellable and non-refundable, rose to $60.8 million, supporting infrastructure build-out. Cash and cash equivalents increased to $21.9 million, and net cash provided by continuing operating activities was $17.4 million for the first half of 2026.